[
  {
    "ts": null,
    "headline": "Structure Therapeutics: The Dark Horse Has Taken The Lead - But Is It Enough?",
    "summary": "Structure Therapeutics Inc. is emerging in oral GLP-1 obesity drugs after Phase II success and rivalsâ setbacks. Click here for this GPCR stock update.",
    "url": "https://finnhub.io/api/news?id=5e34409ab632ba23ff83774cc5d4e091c3b6048a8d26a048614b9a7f4de54791",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771433484,
      "headline": "Structure Therapeutics: The Dark Horse Has Taken The Lead - But Is It Enough?",
      "id": 139139290,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2256411028/image_2256411028.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Structure Therapeutics Inc. is emerging in oral GLP-1 obesity drugs after Phase II success and rivalsâ setbacks. Click here for this GPCR stock update.",
      "url": "https://finnhub.io/api/news?id=5e34409ab632ba23ff83774cc5d4e091c3b6048a8d26a048614b9a7f4de54791"
    }
  },
  {
    "ts": null,
    "headline": "Moderna stock surges as FDA reverses course, agrees to review new flu shot",
    "summary": "Moderna stock jumped more than 6% after the FDA agreed to review the drugmaker's first flu shot of the season, reversing course on a decision to reject the review last week.",
    "url": "https://finnhub.io/api/news?id=c4cb7d4a4314b76c39337f9d93e75c1233a064321d5c8426589e2b7532efd19c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771431643,
      "headline": "Moderna stock surges as FDA reverses course, agrees to review new flu shot",
      "id": 139137841,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Moderna stock jumped more than 6% after the FDA agreed to review the drugmaker's first flu shot of the season, reversing course on a decision to reject the review last week.",
      "url": "https://finnhub.io/api/news?id=c4cb7d4a4314b76c39337f9d93e75c1233a064321d5c8426589e2b7532efd19c"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Colorectal Cancer Trial Win Adds Weight To Oncology Turnaround Story",
    "summary": "Pfizer (NYSE:PFE) reported positive topline results from its pivotal BREAKWATER trial. The study evaluated a BRAFTOVI based combination in previously untreated metastatic colorectal cancer with a BRAF V600E mutation. Results showed a clinically meaningful improvement in progression free survival for patients in the first line setting. The update reflects progress toward a potential new regulatory filing for this colorectal cancer indication. For Pfizer, which has a broad portfolio across...",
    "url": "https://finnhub.io/api/news?id=fdfe23109c91fce90bc3963821e4047178e2635478f5ae64247c46d6a942115d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771423844,
      "headline": "Pfizer Colorectal Cancer Trial Win Adds Weight To Oncology Turnaround Story",
      "id": 139136680,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (NYSE:PFE) reported positive topline results from its pivotal BREAKWATER trial. The study evaluated a BRAFTOVI based combination in previously untreated metastatic colorectal cancer with a BRAF V600E mutation. Results showed a clinically meaningful improvement in progression free survival for patients in the first line setting. The update reflects progress toward a potential new regulatory filing for this colorectal cancer indication. For Pfizer, which has a broad portfolio across...",
      "url": "https://finnhub.io/api/news?id=fdfe23109c91fce90bc3963821e4047178e2635478f5ae64247c46d6a942115d"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer (PFE) Valuation Check After Recent Share Price Rebound And Mixed Earnings Signals",
    "summary": "Why Pfizer (PFE) is on investors’ radar today Pfizer (PFE) is drawing attention after recent trading left the shares at a last close of $27.37, with returns of 6.7% over the past month and 10.0% over the past 3 months. See our latest analysis for Pfizer. Pfizer’s recent move to a US$27.37 share price comes after a 6.7% 1 month share price return and a 10.0% 3 month share price return. Its 1 year total shareholder return of 14.85% contrasts with a 23.18% total shareholder return decline over...",
    "url": "https://finnhub.io/api/news?id=c6f76d4e4d6ef95b9a6ba9bc52b0944deaf0bbc0064fecdc4a429f697c3f7794",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771420094,
      "headline": "Pfizer (PFE) Valuation Check After Recent Share Price Rebound And Mixed Earnings Signals",
      "id": 139134125,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Why Pfizer (PFE) is on investors’ radar today Pfizer (PFE) is drawing attention after recent trading left the shares at a last close of $27.37, with returns of 6.7% over the past month and 10.0% over the past 3 months. See our latest analysis for Pfizer. Pfizer’s recent move to a US$27.37 share price comes after a 6.7% 1 month share price return and a 10.0% 3 month share price return. Its 1 year total shareholder return of 14.85% contrasts with a 23.18% total shareholder return decline over...",
      "url": "https://finnhub.io/api/news?id=c6f76d4e4d6ef95b9a6ba9bc52b0944deaf0bbc0064fecdc4a429f697c3f7794"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game",
    "summary": "Pfizer faces multi-year headwinds from loss of exclusivity and COVID franchise decline, but management highlights transformative M&A and pipeline optionality. Learn more on PFE stock here.",
    "url": "https://finnhub.io/api/news?id=1f217c533254f79a9c2f02e8a8a54def6f9804070b86bfe42a3995347dc1f14e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771414200,
      "headline": "Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game",
      "id": 139137080,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1292440985/image_1292440985.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer faces multi-year headwinds from loss of exclusivity and COVID franchise decline, but management highlights transformative M&A and pipeline optionality. Learn more on PFE stock here.",
      "url": "https://finnhub.io/api/news?id=1f217c533254f79a9c2f02e8a8a54def6f9804070b86bfe42a3995347dc1f14e"
    }
  },
  {
    "ts": null,
    "headline": "FDA agrees to review Moderna’s mRNA flu vaccine application in a reversal",
    "summary": "The FDA is slated to make a decision on the flu shot on Aug. 5, which will allow Moderna to make the vaccine available for the upcoming influenza season.",
    "url": "https://finnhub.io/api/news?id=15ecfffc71f06ee94dbdc6aa1c42240c9266f2e5735b9ca1def96e515833d7a2",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771413435,
      "headline": "FDA agrees to review Moderna’s mRNA flu vaccine application in a reversal",
      "id": 139137408,
      "image": "https://image.cnbcfm.com/api/v1/image/108000894-1771434677666-108000894-1719932078582-gettyimages-2151784856-MODERNA_RSV_VACCINE.jpg?v=1771434697&w=1920&h=1080",
      "related": "PFE",
      "source": "CNBC",
      "summary": "The FDA is slated to make a decision on the flu shot on Aug. 5, which will allow Moderna to make the vaccine available for the upcoming influenza season. ",
      "url": "https://finnhub.io/api/news?id=15ecfffc71f06ee94dbdc6aa1c42240c9266f2e5735b9ca1def96e515833d7a2"
    }
  },
  {
    "ts": null,
    "headline": "$198.39 Bn Active Pharmaceutical Ingredients (API) Markets, 2030 by Synthesis (synthetic, Biotech), Potency (HPAPI), Product (mAbs, Hormones), Drug (OTC, Rx), Application (Diabetes, Oncology)",
    "summary": "The global active pharmaceutical ingredients (API) market is poised to reach USD 198.39 billion by 2030, witnessing a CAGR of 6.6% from USD 144.20 billion in 2025. The API market's growth is significantly driven by expanding oncology, rare disease, and diabetes pipelines, bolstered by peptide-based drugs like Semaglutide. In 2024, the pharmaceutical and biotechnology segment captured the largest market share, reinforced by in-house manufacturing of high-value drugs and increasing outsourcing for",
    "url": "https://finnhub.io/api/news?id=5056b37755ca68c657f44cfca65c6992b88b22f661b559ab6ddc6c78cf05cd46",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771409760,
      "headline": "$198.39 Bn Active Pharmaceutical Ingredients (API) Markets, 2030 by Synthesis (synthetic, Biotech), Potency (HPAPI), Product (mAbs, Hormones), Drug (OTC, Rx), Application (Diabetes, Oncology)",
      "id": 139132635,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The global active pharmaceutical ingredients (API) market is poised to reach USD 198.39 billion by 2030, witnessing a CAGR of 6.6% from USD 144.20 billion in 2025. The API market's growth is significantly driven by expanding oncology, rare disease, and diabetes pipelines, bolstered by peptide-based drugs like Semaglutide. In 2024, the pharmaceutical and biotechnology segment captured the largest market share, reinforced by in-house manufacturing of high-value drugs and increasing outsourcing for",
      "url": "https://finnhub.io/api/news?id=5056b37755ca68c657f44cfca65c6992b88b22f661b559ab6ddc6c78cf05cd46"
    }
  },
  {
    "ts": null,
    "headline": "Fallopian Tube Cancer Market Research Report 2026: AstraZeneca, GlaxoSmithKline, Pfizer and Roche Expand Portfolios and Invest in Novel Therapeutics & Companion Diagnostics - Forecasts 2025-2035",
    "summary": "Fallopian tube cancer, a rare gynecologic cancer, is gaining awareness due to its potential origin for many high-grade serous ovarian cancers. New diagnostics improve early detection and treatment, boosting patient outcomes. Symptoms are often subtle, leading to underdiagnosis and treatment delays. The fallopian tube cancer market is driven by genetic testing demand, BRCA mutation screening, and advancements in targeted therapies like PARP inhibitors. Despite challenges, including high treatment",
    "url": "https://finnhub.io/api/news?id=5cbb343d8673977fca28b7c262bf4d16483ec0da24c123e3f95e5475a6a0074b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771406760,
      "headline": "Fallopian Tube Cancer Market Research Report 2026: AstraZeneca, GlaxoSmithKline, Pfizer and Roche Expand Portfolios and Invest in Novel Therapeutics & Companion Diagnostics - Forecasts 2025-2035",
      "id": 139131566,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Fallopian tube cancer, a rare gynecologic cancer, is gaining awareness due to its potential origin for many high-grade serous ovarian cancers. New diagnostics improve early detection and treatment, boosting patient outcomes. Symptoms are often subtle, leading to underdiagnosis and treatment delays. The fallopian tube cancer market is driven by genetic testing demand, BRCA mutation screening, and advancements in targeted therapies like PARP inhibitors. Despite challenges, including high treatment",
      "url": "https://finnhub.io/api/news?id=5cbb343d8673977fca28b7c262bf4d16483ec0da24c123e3f95e5475a6a0074b"
    }
  },
  {
    "ts": null,
    "headline": "FDA chief Marty Makary says 'everything should be over the counter' unless drug is unsafe or addictive",
    "summary": "Makary said the FDA is looking at prescription drugs like nausea medications and vaginal estrogen, and hopes to make changes this year.",
    "url": "https://finnhub.io/api/news?id=04105639750ceec82f927ba72ef6ce83266b0d6af2f1fef117a869390c1457e0",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771404877,
      "headline": "FDA chief Marty Makary says 'everything should be over the counter' unless drug is unsafe or addictive",
      "id": 139137337,
      "image": "https://image.cnbcfm.com/api/v1/image/108111981-17412749682025-03-06t152858z_1041948067_rc2r7da7wjpm_rtrmadp_0_usa-trump-fda.jpeg?v=1741274989&w=1920&h=1080",
      "related": "PFE",
      "source": "CNBC",
      "summary": "Makary said the FDA is looking at prescription drugs like nausea medications and vaginal estrogen, and hopes to make changes this year. ",
      "url": "https://finnhub.io/api/news?id=04105639750ceec82f927ba72ef6ce83266b0d6af2f1fef117a869390c1457e0"
    }
  }
]